SÍNDROME NEUROLÉPTICO MALIGNO: PRESENTACIÓN DE DOS CASOS Y REVISIÓN DEL TEMA

Juan D. Barrios; Ribana Molino

Submitted October 14, 2024

Published 2026-04-06

Artículos de Investigación

Vol. 16 No. 2 (2003): Revista Médico Científica

NEUROLEPTIC MALlGNANT SYNDROME: PRESENTATION Of TWO CASES

Juan D. Barrios⁺⁻
Ribana Molino⁺⁻

PDF (Español (España))

Citación:

DOI: ND

Published: 2026-04-06

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Abstract

The clinical histories of two patients with diagnostic criteria for Neuroleptic Malignant Syndrome, hospitalized at the Internal Medicine Department of Santo Tomas Hospital, are described.
Both patients were females and had a history of treatment with neuroleptics for different psychiatric disorders, with a later develop ment of muscular rigidity, hyperthermia , alteration of their conscious state, autonomic inestability and increase in the levels of creatine phosphokinase.
A review is made of the Neuroleptic Malignant Syndrome and its treatment.

Downloads

Download data is not yet available.

References

Guze SH, Baxter LR Jr. Current Concepts. Neuroleptic Malignant Syndrome. N Engl J Med 1985; 313: 163 - 6.
Caroff Sn, Mann SC. Neuroleptic Malignant Syndrome. Med Clin North Am 1993; 77: 185 - 202.
Sholevar DP. Neuroleptic Malignant Syndrome. Disponible en URL : http://www.emedicine.com/med/topic2614.htm.
Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic Malignant Syndrome. Br J Anaesth 2000; 85: 129 - 35.
Challoner K. Toxicity, Neuroleptic Agents. Disponible en URL: http://www.emedicine.com/emerg/topic.338.htm.
Simon HB. Hyperthermia. N Engl J Med 1993; 329: 483 - 7.
Heiman-Patterson TD. Neuroleptic Malignant Syndrome and Malignant Hyperthermia. Important issues lor the medical consultant. Med Clin North Am 1993; 77: 477 - 92.
Chan-Tack KM. Neuroleptic Malignant Syndrome Due to Promethazine. South Med J 1999; 92: 1017 - 8.
Singh SP,Giridhar C,AvasthiA. Neuroieptic Malignant Syndrome With Trilluperidol. Sr J Psychiatry 1989; 155: 561 - 5.
Manser TJ, Warner JF. Neuroleptic Malignant Syndrome Associated with Prochlorperazine. South Med J 1990; 83: 73 - 4. 11. Philibert RA, Adam LA, Frank FM. Carney-Doebbeling C. Olanzapine Usage Associated With Neuroleptic Malignant Syndrome. Psychosomatics 2001; 42: 528 - 9.
Serry N, Pradhan S, Sagar R, Gupta SK. Neuroleptic Malignant Syndrome in an Adolescent Receiving Olanzapine-Lithium Combínation Therapy. Pharmacotherapy 2003; 23: 255 - 9.
Reeves RR, Torres RA, Liberto V, Hart RH. Atypical Neuroleptic Malignant Syndrome Associated With Olanzapine.
Pharmacotherapy 2002; 22: 641 - 4.
Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic Malignant Syndrome and Quetiapine (Letter)(erratum publicado en Am J Psychiatry 2002; 156:892). Am J Psychiatry 2002; 159: 149 - 50. 15. Cassidy EM, O'Kearne V. Neuroleptic Malignant Syndrome alter Venlalaxine (Letter). The Lancet 2000; 355: 2164 - 5.
Sharma R, Trappler S, Ng YK, Leeman C. Risperidone-Induced Neuroleptic Malignant Syndrome. Ann Pharmacother 1996 ; 30 : 775 - 8.
Suzuki A, Kondo T, Otani K, Mihara K, Yasui-Furukori N, Sano A, et al. Association 01the Taq1 Polymorphism 01the Dopamine 0 2 Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome. Am J Psychiatry 2001; 158: 1714 - 6.
Patel U,A grawal M. Krishnan P, Niranjan S. Neuroleptic Malignant Syndrome Presenling as Pulmonary Edema and Severe Bronchorrhea. J Natl Med Assoc 2002; 94: 279 - 82.
Srinivasan AV, Murugappan M, Krishnamurthy SG, Sayeed ZA. Neuroleptic Malignant Syndrome. J Neurol Neurosurg Psychiatry 1990; 53: 514 - 6.
Mueller PS, Vester JW, Fermaglich J. Neuroleptic Malignant Syndrome. Successful Treatment with bromocriptine.JAMA 1983; 249: 386 - 8.
HarlandCC,O'LearyMM,WintersR,OwensJ, HayesB,Melikian V. Neuroleptic Malignant Syndrome : a case tor electroconvulsive therapy. Postgrad Med J 1990; 66 (771): 49 - 51.
Padgett R, Lipman E. Use 01 Neuroleptics alter an Episode 01 Neuroleptic Malignant Syndrome. Can J Psychiatry 1989; 34: 323- 5.

Keywords

PDF (Español (España))

Resumen visto - 1 veces
PDF (Español (España)) descargado - 0

Licencia

Content Top

[1] Guze SH, Baxter LR Jr. Current Concepts. Neuroleptic Malignant Syndrome. N Engl J Med 1985; 313: 163 - 6.

[2] Caroff Sn, Mann SC. Neuroleptic Malignant Syndrome. Med Clin North Am 1993; 77: 185 - 202.

[3] Sholevar DP. Neuroleptic Malignant Syndrome. Disponible en URL : http://www.emedicine.com/med/topic2614.htm.

[4] Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic Malignant Syndrome. Br J Anaesth 2000; 85: 129 - 35.

[5] Challoner K. Toxicity, Neuroleptic Agents. Disponible en URL: http://www.emedicine.com/emerg/topic.338.htm.

[6] Simon HB. Hyperthermia. N Engl J Med 1993; 329: 483 - 7.

[7] Heiman-Patterson TD. Neuroleptic Malignant Syndrome and Malignant Hyperthermia. Important issues lor the medical consultant. Med Clin North Am 1993; 77: 477 - 92.

[8] Chan-Tack KM. Neuroleptic Malignant Syndrome Due to Promethazine. South Med J 1999; 92: 1017 - 8.

[9] Singh SP,Giridhar C,AvasthiA. Neuroieptic Malignant Syndrome With Trilluperidol. Sr J Psychiatry 1989; 155: 561 - 5.

[10] Manser TJ, Warner JF. Neuroleptic Malignant Syndrome Associated with Prochlorperazine. South Med J 1990; 83: 73 - 4. 11. Philibert RA, Adam LA, Frank FM. Carney-Doebbeling C. Olanzapine Usage Associated With Neuroleptic Malignant Syndrome. Psychosomatics 2001; 42: 528 - 9.

[11] Serry N, Pradhan S, Sagar R, Gupta SK. Neuroleptic Malignant Syndrome in an Adolescent Receiving Olanzapine-Lithium Combínation Therapy. Pharmacotherapy 2003; 23: 255 - 9.

[12] Reeves RR, Torres RA, Liberto V, Hart RH. Atypical Neuroleptic Malignant Syndrome Associated With Olanzapine.

[13] Pharmacotherapy 2002; 22: 641 - 4.

[14] Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic Malignant Syndrome and Quetiapine (Letter)(erratum publicado en Am J Psychiatry 2002; 156:892). Am J Psychiatry 2002; 159: 149 - 50. 15. Cassidy EM, O'Kearne V. Neuroleptic Malignant Syndrome alter Venlalaxine (Letter). The Lancet 2000; 355: 2164 - 5.

[15] Sharma R, Trappler S, Ng YK, Leeman C. Risperidone-Induced Neuroleptic Malignant Syndrome. Ann Pharmacother 1996 ; 30 : 775 - 8.

[16] Suzuki A, Kondo T, Otani K, Mihara K, Yasui-Furukori N, Sano A, et al. Association 01the Taq1 Polymorphism 01the Dopamine 0 2 Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome. Am J Psychiatry 2001; 158: 1714 - 6.

[17] Patel U,A grawal M. Krishnan P, Niranjan S. Neuroleptic Malignant Syndrome Presenling as Pulmonary Edema and Severe Bronchorrhea. J Natl Med Assoc 2002; 94: 279 - 82.

[18] Srinivasan AV, Murugappan M, Krishnamurthy SG, Sayeed ZA. Neuroleptic Malignant Syndrome. J Neurol Neurosurg Psychiatry 1990; 53: 514 - 6.

[19] Mueller PS, Vester JW, Fermaglich J. Neuroleptic Malignant Syndrome. Successful Treatment with bromocriptine.JAMA 1983; 249: 386 - 8.

[20] HarlandCC,O'LearyMM,WintersR,OwensJ, HayesB,Melikian V. Neuroleptic Malignant Syndrome : a case tor electroconvulsive therapy. Postgrad Med J 1990; 66 (771): 49 - 51.

[21] Padgett R, Lipman E. Use 01 Neuroleptics alter an Episode 01 Neuroleptic Malignant Syndrome. Can J Psychiatry 1989; 34: 323- 5.

Cover image

Abstract

Downloads

References

Keywords

Licencia